T2 Biosystems
T2 Biosystems was a medical diagnostics company that developed the T2Dx rapid pathogen detection platform, enabling hospital laboratories to identify bloodstream infections and antimicrobial resistance directly from blood samples without traditional blood culture. The company ceased operations in early 2026.
- Company typePublic
- Founded2014
- HeadquartersLexington, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What T2 Biosystems does
T2 Biosystems, Inc. was a medical diagnostics company that developed the T2Dx rapid diagnostic platform for detecting sepsis-causing pathogens and antimicrobial resistance directly from patient blood samples, eliminating the need for traditional blood culture. The T2Dx system received de novo FDA authorization in 2014, establishing a first-mover regulatory position in culture-independent blood pathogen detection. The company targeted hospital laboratories and healthcare institutions as its core customer segment and generated revenue through sales of the T2Dx instrument and associated diagnostic consumable panels via an enterprise field-sales motion. Headquartered in Lexington, Massachusetts, and listed on NASDAQ under ticker TTOO, T2 Biosystems pursued international expansion and additional panel FDA submissions as growth vectors.
The company's business model centered on a razor-and-blade hardware/consumables structure, though specific pricing was not publicly disclosed. Enterprise contracts to hospital systems drove instrument placements, with consumable panels representing the recurring revenue layer. Strategic partners included CRG Servicing LLC as a major debt holder (subsequently converted $15M to equity in February 2024) and BARDA, which awarded a $3.7 million base grant in September 2022 with up to $62.0 million in additional option funding tied to clinical and regulatory milestones.
Despite a recognized regulatory moat and meaningful federal-program support, T2 Biosystems failed to reach commercial scale. Revenue contracted from approximately $22.3M in 2022 to $7.2M in 2023 against net losses of roughly $50M, indicating cost-of-revenue exceeded topline. Repeated dilutive financings — including an $8M private placement in May 2024 — could not stem the cash burn. Nasdaq suspended TTOO trading on February 12, 2025; all employees were terminated thereafter. An investment-bank-led sale process failed to find a buyer capable of satisfying secured indebtedness, and on February 3, 2026 the company announced an immediate wind-down and voluntary liquidation. The T2Biosystems.com domain is no longer resolvable, consistent with the company's dissolved operating state.
T2 Biosystems firmographics
Firmographics- Name
- T2 Biosystems
- Legal name
- T2 Biosystems, Inc.
- Website
- https://t2biosystems.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Closed
- Headcount range
- 101–250 employees
- Short description
- T2 Biosystems was a medical diagnostics company that developed the T2Dx rapid pathogen detection platform, enabling hospital laboratories to identify bloodstream infections and antimicrobial resistance directly from blood samples without traditional blood culture. The company ceased operations in early 2026.
- Ownership category
- akta.pro rank
T2 Biosystems industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (33911)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)
Keywords
Where T2 Biosystems is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
T2 Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Diagnostics Equipment and Consumables: T2 Biosystems generated revenue through sales of its T2Dx diagnostic instrument system and associated diagnostic panels/consumables to healthcare institutions including hospitals and laboratories.
Go-to-market motion1 record
Distribution channels1 record
T2 Biosystems product offering
Product offeringCore offering
T2 Biosystems developed and sold the T2Dx Instrument, a rapid diagnostic system that identifies sepsis-causing pathogens and antimicrobial resistance directly from whole blood samples without requiring traditional blood culture. The company offered the instrument together with associated diagnostic panels/consumables to hospital laboratories and healthcare institutions for time-critical bloodstream infection diagnosis.
Product overview
T2 Biosystems offered a single core product platform, the T2Dx Instrument, which was a rapid diagnostic system for detecting pathogens and antibiotic resistance markers directly from blood samples. The company's proprietary technology eliminated the need for traditional blood culture methods, enabling faster diagnosis of sepsis and other bloodstream infections.
Differentiator
Problem solved
Functional benefit
Products and services
- T2Dx Instrument
Companies that use T2 Biosystems
Customer profileSegments1 record
Ideal customer profiles1 record
T2 Biosystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
T2 Biosystems partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights2 records
T2 Biosystems competitors and assessment
Company assessmentDirect peers
- bioMérieux: Global leader in in vitro diagnostics and clinical microbiology. Directly comparable to T2 Biosystems as both sell blood-pathogen identification and antimicrobial resistance testing solutions to hospital labs, with bioMérieux's BioFire and VITEK lines representing the dominant direct-from-blood molecular and culture-based alternatives to T2Dx.
- Cepheid (Danaher): Molecular diagnostics company (owned by Danaher) whose GeneXpert system provides rapid PCR-based pathogen detection including from blood samples. Closely comparable to T2Dx as a direct-from-specimen rapid molecular platform sold to hospital and reference laboratories.
- Accelerate Diagnostics: Commercial-stage company developing rapid identification and antimicrobial susceptibility testing directly from patient samples, including blood. Direct competitor in the rapid sepsis/AST diagnostics niche that T2Dx targeted.
- GenMark Diagnostics: Molecular diagnostics company (acquired by Roche) whose ePlex system provides rapid syndromic and blood-pathogen testing for hospital labs. Direct comparator to T2Dx as a sample-to-answer molecular platform serving similar sepsis/bloodstream-infection use cases.
Broad incumbents
- Becton, Dickinson and Company (BD): Large incumbent in clinical microbiology, blood culture, and molecular diagnostics (BD MAX, BD Phoenix, BD BACTEC). Overlaps directly with T2's hospital-lab customer base and sepsis/bloodstream-infection diagnostic workflow, though BD's portfolio is far broader.
- Roche Diagnostics: Global diagnostics incumbent offering molecular, clinical chemistry, and microbiology solutions (incl. cobas and GenMark ePlex post-acquisition). Comparable to T2 as a hospital-focused IVD player with overlapping blood-pathogen molecular testing capabilities.
- Hologic: Diversified diagnostics and women's health company whose molecular diagnostics business (e.g., Panther system, BioFire acquisition history) competes in rapid pathogen detection. Comparable to T2 as a molecular-IVD peer serving hospital labs.
- QIAGEN: Global molecular diagnostics and sample-technology company with products in infectious disease testing and IVD reagent manufacturing. Overlaps with T2 in the broader molecular IVD and infectious-disease workflow serving clinical labs.
Emerging players
- Tetracore: Specialized developer of molecular and immunodiagnostic assays for infectious disease and biothreat agents, with historical BARDA funding overlap with T2. Comparable as a niche, technology-focused molecular diagnostics peer in the biodefense and sepsis-adjacent space.
- Qvella: Early-stage diagnostics company developing rapid pathogen identification directly from blood without culture, conceptually mirroring T2Dx's core workflow. Comparable as an emerging competitor in the direct-from-blood rapid ID niche.
Market position
Weaknesses1 record
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
T2 Biosystems social profiles
Digital presenceT2 Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
T2 Biosystems leadership team
Management profileNumber of profiles
Profiles5 records
T2 Biosystems funding detail
Funding detailFunding overview
Funding rounds14 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
T2 Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about T2 Biosystems
What does T2 Biosystems do?
T2 Biosystems developed and sold the T2Dx Instrument, a rapid diagnostic system that identifies sepsis-causing pathogens and antimicrobial resistance directly from whole blood samples without requiring traditional blood culture. The company offered the instrument together with associated diagnostic panels/consumables to hospital laboratories and healthcare institutions for time-critical bloodstream infection diagnosis.
Is T2 Biosystems a public or private company?
T2 Biosystems is a public company. It is classified as public and is currently closed.
When was T2 Biosystems founded?
T2 Biosystems was founded in 2014. It employs 101 to 250 people.
Where is T2 Biosystems based?
T2 Biosystems is headquartered in Lexington, United States, in the North America region.
How does T2 Biosystems make money?
One revenue line is on record: medical Diagnostics Equipment and Consumables.
Who are T2 Biosystems's main competitors?
Direct peers on record are bioMérieux, Cepheid (Danaher), Accelerate Diagnostics and GenMark Diagnostics. Broad incumbents are Becton, Dickinson and Company (BD), Roche Diagnostics, Hologic and QIAGEN. Emerging players are Tetracore and Qvella.
Does T2 Biosystems have an API?
No public API is recorded for T2 Biosystems.
What industry is T2 Biosystems in?
T2 Biosystems's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology. Its NAICS code is 325413 and its SIC code is 2835.